Yellow Fever – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Yellow Fever – Pipeline Review, H2 2016’, provides an overview of the Yellow Fever pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Yellow Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Yellow Fever and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Yellow Fever

The report reviews pipeline therapeutics for Yellow Fever by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Yellow Fever therapeutics and enlists all their major and minor projects

The report assesses Yellow Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Yellow Fever

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Yellow Fever

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Yellow Fever pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Arno Therapeutics, Inc.

Bavarian Nordic A/S

BioCryst Pharmaceuticals, Inc.

Ennaid Therapeutics, LLC

iBio, Inc.

Johnson & Johnson

NewLink Genetics Corporation

Panacea Biotec Limited

Sihuan Pharmaceutical Holdings Group Ltd.

Valneva SE

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Yellow Fever Overview 7

Therapeutics Development 8

Pipeline Products for Yellow Fever - Overview 8

Pipeline Products for Yellow Fever - Comparative Analysis 9

Yellow Fever - Therapeutics under Development by Companies 10

Yellow Fever - Therapeutics under Investigation by Universities/Institutes 11

Yellow Fever - Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Yellow Fever - Products under Development by Companies 14

Yellow Fever - Products under Investigation by Universities/Institutes 15

Yellow Fever - Companies Involved in Therapeutics Development 16

Arno Therapeutics, Inc. 16

Bavarian Nordic A/S 17

BioCryst Pharmaceuticals, Inc. 18

Ennaid Therapeutics, LLC 19

iBio, Inc. 20

Johnson & Johnson 21

NewLink Genetics Corporation 22

Panacea Biotec Limited 23

Sihuan Pharmaceutical Holdings Group Ltd. 24

Valneva SE 25

Yellow Fever - Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Combination Products 27

Assessment by Target 28

Assessment by Mechanism of Action 30

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Drug Profiles 36

(arenavirus + yellow fever) vaccine - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

AR-12 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

BCX-4430 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

DEF-201 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

FDX-000 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

JK-05 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

RKP-00156 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Small Molecule to Inhibit NS4B for Dengue and Yellow Fever Virus Infections - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Synthetic Peptides for Yellow Fever - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

XRX-001 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

yellow fever [strain YF17D] vaccine - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

yellow fever vaccine - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

yellow fever vaccine - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

yellow fever vaccine - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

yellow fever vaccine - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

yellow fever vaccine - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

yellow fever vaccine - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

yellow fever vaccine - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

yellow fever vaccine - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Yellow Fever - Dormant Projects 61

Yellow Fever - Product Development Milestones 62

Featured News & Press Releases 62

Jul 27, 2016: Bavarian Nordic Announces Initiation of NIH Sponsored Phase 1 Trial of MVA-BN-based Yellow Fever Vaccine 62

Jul 27, 2016: NIH launches early-stage yellow fever vaccine trial 62

Apr 07, 2011: Xcellerex Announces Positive Results From Phase I Clinical Trial Of XRX-001 63

Appendix 65

Methodology 65

Coverage 65

Secondary Research 65

Primary Research 65

Expert Panel Validation 65

Contact Us 65

Disclaimer 66

List of Tables

List of Tables

Number of Products under Development for Yellow Fever, H2 2016 8

Number of Products under Development for Yellow Fever – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Yellow Fever – Pipeline by Arno Therapeutics, Inc., H2 2016 16

Yellow Fever – Pipeline by Bavarian Nordic A/S, H2 2016 17

Yellow Fever – Pipeline by BioCryst Pharmaceuticals, Inc., H2 2016 18

Yellow Fever – Pipeline by Ennaid Therapeutics, LLC, H2 2016 19

Yellow Fever – Pipeline by iBio, Inc., H2 2016 20

Yellow Fever – Pipeline by Johnson & Johnson, H2 2016 21

Yellow Fever – Pipeline by NewLink Genetics Corporation, H2 2016 22

Yellow Fever – Pipeline by Panacea Biotec Limited, H2 2016 23

Yellow Fever – Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H2 2016 24

Yellow Fever – Pipeline by Valneva SE, H2 2016 25

Assessment by Monotherapy Products, H2 2016 26

Assessment by Combination Products, H2 2016 27

Number of Products by Stage and Target, H2 2016 29

Number of Products by Stage and Mechanism of Action, H2 2016 31

Number of Products by Stage and Route of Administration, H2 2016 33

Number of Products by Stage and Molecule Type, H2 2016 35

Yellow Fever – Dormant Projects, H2 2016 61

List of Figures

List of Figures

Number of Products under Development for Yellow Fever, H2 2016 8

Number of Products under Development for Yellow Fever – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 26

Number of Products by Top 10 Targets, H2 2016 28

Number of Products by Stage and Top 10 Targets, H2 2016 28

Number of Products by Top 10 Mechanism of Actions, H2 2016 30

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 30

Number of Products by Routes of Administration, H2 2016 32

Number of Products by Stage and Routes of Administration, H2 2016 32

Number of Products by Top 10 Molecule Types, H2 2016 34

Number of Products by Stage and Top 10 Molecule Types, H2 2016 34

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports